Neurology infusion suites are a high-revenue, high-complexity billing area. Get the HCPCS J-codes and CPT pairings right and a 50-patient practice generates $200K+ per quarter from biologics alone. Get them wrong and you face authorization denials, takebacks, and audit risk. Here’s how AMS Solutions bills infusion biologics in 2026.
The 2026 biologic landscape
For multiple sclerosis: Ocrevus (ocrelizumab, J2350), Tysabri (natalizumab, J2323), Lemtrada (alemtuzumab, J0202). For chronic migraine: Vyepti (eptinezumab, J0593), Aimovig (erenumab, J3032), Ajovy (fremanezumab, J3245), Emgality (galcanezumab, J3000). For neuromyelitis optica: Soliris (eculizumab, J1300), Uplizna (inebilizumab, J2799). Each has distinct administration protocols, billing rhythms, and prior-auth playbooks.
HCPCS J-codes and CPT pairing
Every infusion claim has two layers: the drug (J-code) and the administration (CPT). For a 6-month Ocrevus infusion: J2350 with units billed per mg, plus 96413 (first hour) + 96415 (each additional hour) + 96361 (each additional hour). The administration codes drive E/M time-based reimbursement; the J-code drives the drug cost passthrough.
Prior auth: step-therapy by payer
Anthem BCBS: Requires documented failure of glatiramer or interferon for first-line MS biologics. Vyepti requires failed Aimovig OR Ajovy. UnitedHealthcare: Step-therapy from interferon to Ocrevus; Aimovig before Vyepti. Aetna: Pre-authorization required for any biologic; preferred is Ocrevus over Tysabri due to PML risk. Cigna: Has clinical pathways requiring neurologist consultation for each biologic. Humana Medicare: Coverage follows CMS LCD; Vyepti requires documentation of 4+ migraines/month for 3 consecutive months.
The infusion suite billing checklist
- Prior auth documented in PM system with auth number + valid date range
- Diagnosis code matches LCD (e.g., G35 multiple sclerosis for Ocrevus)
- J-code units = drug mg quantity (not dose count)
- CPT 96413 + 96415 chained correctly for infusion length
- NDC code attached for drugs requiring NDC-based pricing
- Modifier JW for any wasted drug (Medicare requires this)
- Place of service 11 (office) or 19/22 (off-campus hospital outpatient) — payer-specific
- Diagnosis pointer correctly mapping each CPT to G35, G44.x, or G36.x
Top 5 denial reasons + appeal templates
1) Missing prior auth. Resubmit with the auth number after re-confirming validity. 2) NDC mismatch. The drug NDC must exactly match the package billed; check the unit-of-measure. 3) Step-therapy not met. Appeal with documented failure of prior therapy + clinical rationale. 4) Frequency limit exceeded. For Ocrevus q6mo, ensure your last claim was ≥150 days prior. 5) Bundling with E/M. If patient had an E/M same day, use modifier 25 — but only when documentation supports a separately identifiable service.
ICN tracking for biologics
Each infusion claim generates a payer ICN that you’ll need for appeals. Build an infusion-specific tracking sheet: patient, drug, date of service, NDC, units, J-code, ICN, and EOB status. When an appeal is filed, attach the original ICN — Medicare and most commercial payers require this for appeal eligibility.
Want help building a neurology infusion-suite billing workflow? Our team has billed biologics for 30+ neurology practices since 1992. Call (214) 571-6317 or book a 30-minute review. Grab our free 2026 Neurology CPT Cheat Sheet while you’re here.
